Drugs / MR-Vac
MR-Vac
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy3 trials | ||||||
| Phase 1/2 | NCT05073003 Background | Oct 2021 → Jun 2025 | diarrheal disease | GlaxoSmithKline | Completed | Missed primary |
| Phase 2 | NCT06663436 Background | Nov 2024 → Oct 2025 | diarrheal disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT02699099 Background | May 2017 → Mar 2018 | malaria | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MR-Vac | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02699099 ↗ |
| Known as | Live attenuated measles virus and rubella virus vaccine (MR-Vac) | “Live attenuated measles virus and rubella virus vaccine (MR-Vac)” NCT02699099 ↗ |
| Modality | Vaccine | “combined measles and rubella vaccine” NCT02699099 ↗ |
| Route | Subcutaneous | “Subcutaneous injection of a combined measles and rubella vaccine (1 dose)” NCT02699099 ↗ |